DMSI Dermisonics Inc New (CE)

Dermisonics, Inc. (OTCBB:DMSI), a medical device company with its focus on the development of an ultrasonically assisted transdermal drug-delivery technology, announced today that the United States Patent and Trademark Office has issued a notice of allowance for the approval of the most substantial patent claims for the Medi-Cap(TM), a groundbreaking transdermal drug-delivery device. The Medi-Cap(TM) is a two-part transdermal patch system consisting of a Transducer Coupler(TM) and a Patch-Cap(TM), which contains the drug itself, suspended in liquid, as injectable pharmaceutical compounds are formulated today. The Medi-Cap(TM) is designed specifically for ultrasonic and other electronic drug delivery applications where a conventional patch is unsuitable due to reliance on a mixture of the drug and an adhesive substance. Such conventional patches run the risk of contaminating certain drugs and altering their performance. The Patch-Cap(TM) portion of the Medi-Cap(TM) uses an absorbent pad to store the drug until ultrasound, delivered from the snap-on Transducer Coupler(TM), liberates the drug from the Patch-Cap(TM) and onto the patient's skin surface. From there ultrasound can be employed to dilate the skin pores and deliver the drug into and through the in vitro dermis. The Transducer Coupler(TM) contains up to four miniature ultrasonic transducers and is powered by the U-Strip(TM) Ultrasonic Drug Delivery System. The Patch-Cap(TM) contains the pharmaceutical compound and is disposable. The current design is capable of holding up to 75 units of insulin, enough for a two-day supply for most insulin dependant, injecting diabetics. The Medi-Cap(TM) disposable drug patch component is designed to be replaced every 24 to 36 hours. The Medi-Cap(TM) System The Patch-Cap(TM) component contains the pharmaceutical compound and is disposable. Within the Patch-Cap(TM) there are no adhesives required, which might contaminate the drug at the time of application and delivery. The Medi-Cap(TM) replaces ordinary transdermal patches and is a critical and integral part of the U-Strip(TM) ultrasonic transdermal delivery device, acting as the actual reservoir for the drug as well as being the delivery component of the system. Dermisonics, Inc. CEO Bruce Haglund noted, "The allowance of multiple claims in this patent application is an important milestone achievement for the Company. The patent covers most of the essential elements of the U-Strip(TM), including the concept of enhancing the transdermal delivery of pharmaceutical compounds via ultrasonic techniques, the potential delivery of multiple substances through a patch and the Patch Cap(TM)'s on/off valve that helps control the size and timing of the dosage." About Dermisonics, Inc. Dermisonics Inc. is a medical device company that is focused on the ongoing development, testing and eventual commercialization of a transdermal patch that has been designed to facilitate the efficient and needle-free delivery of heavy molecular drugs into the system. The U-Strip(TM) is a drug delivery system incorporating a transdermal patch in combination with microelectronics and ultrasonic technology. Tests have shown that this system facilitates the transdermal delivery of Insulin as well as potentially at least 175 other existing drugs that at present cannot be effectively delivered through the pores of the skin using conventionally available transdermal technology due to their large molecular size. For additional information, please visit http://www.dermisonics.com. Legal Notice Regarding Forward-Looking Statements This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although the Company believes that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, it can give no assurance that such expectations and assumptions will prove to have been correct. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to adverse economic conditions, intense competition, lack of meaningful research results, entry of new competitors and products, adverse federal, state and local government regulation, inadequate capital, unexpected costs and operating deficits, increases in general and administrative costs, termination of contracts or agreements, technological obsolescence of the Company's products, technical problems with the Company's research and products, price increases for supplies and components, litigation and administrative proceedings involving the Company, the possible acquisition of new businesses or that result in operating losses or that do not perform as anticipated, unanticipated losses, the possible fluctuation and volatility of the Company's operating results, financial condition and stock price, losses incurred in litigating and settling cases, dilution in the Company's ownership of its business, adverse publicity and news coverage, inability to carry out research, development and commercialization plans, loss or retirement of key executives and research scientists, changes in interest rates, inflationary factors, and other specific risks. In addition, other factors that could cause actual results to differ materially are discussed in the Company's most recent Form 10-QSB and Form 10-KSB filings with the Securities and Exchange Commission.